# A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)

> **NCT06025344** · PHASE1 · COMPLETED · sponsor: **TrippBio, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Relative Bioavailability

## Interventions

- **DRUG:** PanCytoVir™ 100 mg/mL oral suspension
- **DRUG:** Probenecid 500 mg

## Key facts

- **NCT ID:** NCT06025344
- **Lead sponsor:** TrippBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-10-15
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06025344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06025344, "A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06025344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*